Genetic aberrations in soft tissue leiomyosarcoma

Yang, Jilong; Du, Xiaoling; Chen, Kexin; Ylipää, Antti; Lazar, Alexander J.F.; Trent, Jonathan; Lev, Dina; Pollock, Raphael; Hao, Xishan; Hunt, Kelly; Zhang, Wei

doi:10.1016/j.canlet.2008.06.013

« Previous Next »Cancer Letters
Volume 275, Issue 1 , Pages 1-8, 8 March 2009

Genetic aberrations in soft tissue leiomyosarcoma

Jilong Yang
- Department of Bone and Soft Tissue Tumor, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 30060, China
Xiaoling Du
- Department of Diagnostics, Tianjin Medical University, Tianjin 30060, China
Kexin Chen
- Department of Epidemiology and Biostatistics, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 30060, China
Antti Ylipää
- Department of Pathology, Unit 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Department of Signal Processing, Tampere University of Technology, Tampere, Finland
Alexander J.F. Lazar
- Department of Pathology, Unit 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Sarcoma Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Jonathan Trent
- Department of Sarcoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- Sarcoma Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Dina Lev
- Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- Sarcoma Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Raphael Pollock
- Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
- Sarcoma Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Xishan Hao
- Department of Bone and Soft Tissue Tumor, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 30060, China
- Department of Diagnostics, Tianjin Medical University, Tianjin 30060, China
- Department of Epidemiology and Biostatistics, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin 30060, China
Kelly Hunt
- Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Wei Zhang
- Department of Pathology, Unit 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Corresponding author. Tel.: +1 713 745 1103; fax: +1 713 792 5549.

Received 5 April 2008; received in revised form 5 June 2008; accepted 16 June 2008. published online 24 July 2008.

Abstract

Leiomyosarcoma is a malignant mesenchymal tumor composed of cells showing smooth muscle differentiation. This tumor usually occurs in middle-aged or older adults, and forms a significant percentage of retroperitoneal, vascular, extremity, and uterine sarcomas. Leiomyosarcomas are most often associated with complex karyotypes with numerous chromosomal gains and losses. Some of these cytogenetic and molecular genetic aberrations correlate with histopathologic features and clinical outcomes. Identification of genetic alterations with specific identification of oncogenes and tumor suppressor genes may lead to additional insights into the tumorigenesis of leiomyosarcoma and the opportunity to confer the benefits of targeted therapy.

Keywords: Leiomyosarcoma, Genetic alteration, Array CGH, Karyotype, Sarcoma